Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: FTT001
MIFTS: 60

Fatty Liver Disease

Categories: Gastrointestinal diseases, Metabolic diseases, Liver diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Fatty Liver Disease

About this section

MalaCards integrated aliases for Fatty Liver Disease:

Name: Fatty Liver Disease 12 43 15
Fatty Liver 76 55 44 73
Fatty Liver, Alcoholic 44 73
Alcoholic Fatty Liver 12
Fatty Change of Liver 12
Fatty Liver Alcoholic 55
Steatosis of Liver 12
Hepatic Lipidosis 12
Steatohepatitis 73

Classifications:

MalaCards categories:
Global: Metabolic diseases
Anatomical: Gastrointestinal diseases Liver diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:9452
ICD10 33 K70.0
ICD9CM 35 571.0
Sources

Summaries for Fatty Liver Disease

About this section
MedlinePlus : 43 What is fatty liver disease? Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Fatty liver disease is a condition in which fat builds up in your liver. There are two main types: Nonalcoholic fatty liver disease (NAFLD) Alcoholic fatty liver disease, also called alcoholic steatohepatitis What is nonalcoholic fatty liver disease (NAFLD)? NAFLD is a type of fatty liver disease that is not related to heavy alcohol use. There are two kinds: Simple fatty liver, in which you have fat in your liver but little or no inflammation or liver cell damage. Simple fatty liver typically does not get bad enough to cause liver damage or complications. Nonalcoholic steatohepatitis (NASH), in which you have inflammation and liver cell damage, as well as fat in your liver. Inflammation and liver cell damage can cause fibrosis, or scarring, of the liver. NASH may lead to cirrhosis or liver cancer. What is alcoholic fatty liver disease? Alcoholic fatty liver disease is due to heavy alcohol use. Your liver breaks down most of the alcohol you drink, so it can be removed from your body. But the process of breaking it down can generate harmful substances. These substances can damage liver cells, promote inflammation, and weaken your body's natural defenses. The more alcohol that you drink, the more you damage your liver. Alcoholic fatty liver disease is the earliest stage of alcohol-related liver disease. The next stages are alcoholic hepatitis and cirrhosis. Who gets fatty liver disease? Researchers do not know the cause of nonalcoholic fatty liver (NAFLD). They do know that it is more common in people who Have type 2 diabetes and prediabetes Have obesity Are middle aged or older (although children can also get it) Are Hispanic, followed by non-Hispanic whites. It is less common in African Americans. Have high levels of fats in the blood, such as cholesterol and triglycerides Have high blood pressure Take certain drugs, such as corticosteroids and some cancer drugs Have certain metabolic disorders, including metabolic syndrome Have rapid weight loss Have certain infections, such as hepatitis C Have been exposed to some toxins NAFLD affects about 25 percent of people in the world. As the rates of obesity, type 2 diabetes, and high cholesterol are rising in the United States, so is the rate of NAFLD. NAFLD is the most common chronic liver disorder in the United States. Alcoholic fatty liver disease only happens in people who are heavy drinkers, especially those who have been drinking for a long period of time. The risk is higher for heavy drinkers who are women, have obesity, or have certain genetic mutations. What are the symptoms of fatty liver disease? Both NAFLD and alcoholic fatty liver disease are usually silent diseases with few or no symptoms. If you do have symptoms, you may feel tired or have discomfort in the upper right side of your abdomen. How do I know if I have fatty liver disease? Because there are often no symptoms, it is not easy to find fatty liver disease. Your doctor may suspect that you have it if you get abnormal results on liver tests that you had for other reasons. To make a diagnosis, your doctor will use Your medical history A physical exam Various tests, including blood and imaging tests, and sometimes a biopsy As part of the medical history, your doctor will ask about your alcohol use, to find out whether fat in your liver is a sign of alcoholic fatty liver disease or nonalcoholic fatty liver (NAFLD). He or she will also ask which medicines you take, to try to determine whether a medicine is causing your NAFLD. During the physical exam, your doctor will examine your body and check your weight and height. Your doctor will look for signs of fatty liver disease, such as An enlarged liver Signs of cirrhosis, such as jaundice, a condition that causes your skin and whites of your eyes to turn yellow You will likely have blood tests, including liver function tests and blood count tests. In some cases you may also have imaging tests, like those that check for fat in the liver and the stiffness of your liver. Liver stiffness can mean fibrosis, which is scarring of the liver. In some cases you may also need a liver biopsy to confirm the diagnosis, and to check how bad the liver damage is. What are the treatments for fatty liver disease? Doctors recommend weight loss for nonalcoholic fatty liver. Weight loss can reduce fat in the liver, inflammation, and fibrosis. If your doctor thinks that a certain medicine is the cause of your NAFLD, you should stop taking that medicine. But check with your doctor before stopping the medicine. You may need to get off the medicine gradually, and you might need to switch to another medicine instead. There are no medicines that have been approved to treat NAFLD. Studies are investigating whether a certain diabetes medicine or Vitamin E can help, but more studies are needed. The most important part of treating alcohol-related fatty liver disease is to stop drinking alcohol. If you need help doing that, you may want to see a therapist or participate in an alcohol recovery program. There are also medicines that can help, either by reducing your cravings or making you feel sick if you drink alcohol. Both alcoholic fatty liver disease and one type of nonalcoholic fatty liver disease (nonalcoholic steatohepatitis) can lead to cirrhosis. Doctors can treat the health problems caused by cirrhosis with medicines, operations, and other medical procedures. If the cirrhosis leads to liver failure, you may need a liver transplant. What are some lifestyle changes that can help with fatty liver disease? If you have any of the types of fatty liver disease, there are some lifestyle changes that can help: Eat a healthy diet, limiting salt and sugar, plus eating lots of fruits, vegetables, and whole grains Get vaccinations for hepatitis A and B, the flu and pneumococcal disease. If you get hepatitis A or B along with fatty liver, it is more likely to lead to liver failure. People with chronic liver disease are more likely to get infections, so the other two vaccinations are also important. Get regular exercise, which can help you lose weight and reduce fat in the liver Talk with your doctor before using dietary supplements, such as vitamins, or any complementary or alternative medicines or medical practices. Some herbal remedies can damage your liver.

MalaCards based summary : Fatty Liver Disease, also known as fatty liver, is related to nonalcoholic steatohepatitis and hepatitis. An important gene associated with Fatty Liver Disease is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1
MALAT1 promotes hepatic steatosis and insulin resistance by increasing nuclear SREBP-1c protein stability.
Dysfunction Pattern: Regulation), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha). The drugs Zinc and Pioglitazone have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and heart, and related phenotypes are homeostasis/metabolism and adipose tissue

Disease Ontology : 12 A lipid storage disease characterized by the accumulation of large vacuoles of triglyceride fat in liver cells via the process of steatosis.

Wikipedia : 76 Fatty liver is a reversible condition wherein large vacuoles of triglyceride fat accumulate in liver... more...

Sources

Related Diseases for Fatty Liver Disease

About this section

Diseases related to Fatty Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 163)
# Related Disease Score Top Affiliating Genes
1 nonalcoholic steatohepatitis 32.1 ADIPOQ GPT INS KRT18 LEP PNPLA3
2 hepatitis 31.6 GPT MAPK8 SLC17A5 TNF
3 liver disease 31.4 ADIPOQ ADIPOR2 CYP2E1 GPT INS KRT18
4 apnea, obstructive sleep 31.3 ADIPOQ INS LEP TNF
5 arteries, anomalies of 31.3 ADIPOQ INS LEP TNF
6 sleep apnea 31.0 ADIPOQ INS LEP LEPR TNF
7 pancreas disease 30.9 INS LEP TNF
8 morbid obesity 30.9 ADIPOQ INS LEP LEPR RETN
9 viral hepatitis 30.8 GPT KRT18 SLC17A5 TNF
10 polycystic ovary syndrome 30.7 INS INSR LEP
11 alcoholic liver cirrhosis 30.5 CYP2E1 PNPLA3 SLC17A5
12 coronary heart disease 1 30.4 ADIPOQ INS MTTP RETN
13 vascular disease 30.4 ADIPOQ INS RETN TNF
14 hypertension, essential 30.3 ADIPOQ INS INSR LEP RETN
15 insulin-like growth factor i 30.3 INS INSR LEP
16 liver cirrhosis 30.0 CYP2E1 GPT MALAT1 SLC17A5
17 glucose intolerance 29.9 ADIPOQ INS INSR LEP LEPR RETN
18 overnutrition 29.7 ADIPOQ INS LEP LEPR RETN SREBF1
19 hyperglycemia 29.3 ADIPOQ INS INSR LEP MALAT1
20 diabetes mellitus 29.1 ADIPOQ INS INSR LEP MALAT1 MAPK8
21 diabetes mellitus, noninsulin-dependent 28.2 ADIPOQ ADIPOR2 GPT INS INSR LEP
22 nonalcoholic fatty liver disease 12.7
23 fatty liver disease, nonalcoholic 1 12.6
24 fatty liver disease, nonalcoholic 2 12.2
25 visceral steatosis, congenital 11.1
26 paraquat poisoning 11.0 GPT SLC17A5
27 nontuberculous mycobacterial lung disease 10.9 ADIPOQ LEP TNF
28 idiopathic edema 10.9 ADIPOQ INS PPARA
29 prediabetes syndrome 10.9 ADIPOQ INS LEP
30 endocrine pancreas disease 10.9 ADIPOQ INS LEP
31 acquired generalized lipodystrophy 10.9 ADIPOQ LEP RETN
32 obesity-hypoventilation syndrome 10.9 ADIPOQ LEP RETN
33 pyridoxine deficiency 10.9 GPT SLC17A5
34 idiopathic recurrent pericarditis 10.9 ADIPOQ LEP RETN
35 scrub typhus 10.9 GPT SLC17A5 TNF
36 protein-energy malnutrition 10.9 GPT LEP TNF
37 coronary artery aneurysm 10.8 ADIPOQ LEP RETN
38 morbid obesity and spermatogenic failure 10.8
39 obstructive jaundice 10.8 GPT SLC17A5 TNF
40 severe pre-eclampsia 10.8 ADIPOQ LEP LEPR
41 lipid storage disease 10.8 ADIPOQ INS PNPLA3 SREBF1
42 hepatic encephalopathy 10.8 GPT SLC17A5 TNF
43 insulin autoimmune syndrome 10.8 INS INSR
44 eating disorder 10.7 ADIPOQ LEP LEPR
45 alcohol abuse 10.7 CYP2E1 GPT SLC17A5
46 lipodystrophy, familial partial, type 2 10.7 INS LEP
47 uremia 10.7 INS LEP RETN
48 atherosclerosis susceptibility 10.7 ADIPOQ INS TNF
49 inherited metabolic disorder 10.6 ADIPOQ INS LEP PNPLA3 SREBF1
50 abdominal obesity-metabolic syndrome 1 10.6 ADIPOQ INS LEP MTTP

Comorbidity relations with Fatty Liver Disease via Phenotypic Disease Network (PDN):


Alcohol Abuse Alcoholic Hepatitis
Alcoholic Liver Cirrhosis

Graphical network of the top 20 diseases related to Fatty Liver Disease:



Diseases related to Fatty Liver Disease
Sources

Symptoms & Phenotypes for Fatty Liver Disease

About this section

MGI Mouse Phenotypes related to Fatty Liver Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.19 MLXIPL MTTP PNPLA3 PPARA RETN SLC17A5
2 adipose tissue MP:0005375 10.14 PPARA RETN TNF MLXIPL INSR ADIPOQ
3 growth/size/body region MP:0005378 10.1 TNF MTTP PPARA SLC17A5 INS MAPK8
4 cardiovascular system MP:0005385 10.07 TNF MTTP PPARA MAPK8 INSR ADIPOQ
5 liver/biliary system MP:0005370 10.06 MTTP PPARA RETN SREBF1 TNF INSR
6 mortality/aging MP:0010768 9.8 MLXIPL MTTP PPARA SLC17A5 SREBF1 TNF
7 muscle MP:0005369 9.23 TNF PPARA MAPK8 INSR ADIPOQ LEP
Sources

Drugs & Therapeutics for Fatty Liver Disease

About this section

Drugs for Fatty Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 432)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6 23994
2
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 111025-46-8 4829
3
Amlodipine Approved Phase 4 88150-42-9 2162
4
Simvastatin Approved Phase 4,Not Applicable 79902-63-9 54454
5
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 657-24-9 14219 4091
6
Ribavirin Approved Phase 4,Phase 3,Not Applicable 36791-04-5 37542
7
Losartan Approved Phase 4,Phase 3,Phase 2 114798-26-4 3961
8
Ezetimibe Approved Phase 4,Phase 2 163222-33-1 150311
9
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
10
Valsartan Approved, Investigational Phase 4,Phase 3 137862-53-4 60846
11
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3 58-93-5 3639
12
Liraglutide Approved Phase 4,Phase 3,Phase 2 204656-20-2 44147092
13
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
14
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
15
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
16
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Not Applicable 122320-73-4 77999
17
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
18
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
19
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
20
Peginterferon alfa-2a Approved, Investigational Phase 4,Not Applicable 198153-51-4 5360545
21
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
22
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
23
Orlistat Approved, Investigational Phase 4,Phase 2 96829-58-2 3034010
24
Menthol Approved Phase 4,Not Applicable 2216-51-5 16666
25
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
26
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 5754
27
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
28
Rifampicin Approved Phase 4,Phase 1 13292-46-1 5458213 5381226
29
Gliclazide Approved Phase 4 21187-98-4 3475
30
Cortisone acetate Approved, Investigational Phase 4 1950-04-4, 50-04-4 5745
31
Tamoxifen Approved Phase 4 10540-29-1 2733526
32
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
33
Efavirenz Approved, Investigational Phase 4,Not Applicable 154598-52-4 64139
34
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
35
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
36
Empagliflozin Approved Phase 4,Phase 3,Not Applicable 864070-44-0
37
Insulin Aspart Approved Phase 4 116094-23-6 16132418
38
Insulin Glargine Approved Phase 4,Phase 2 160337-95-1
39
Insulin Detemir Approved Phase 4 169148-63-4 5311023
40
Rifaximin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 80621-81-4 6436173
41
Racepinephrine Approved Phase 4,Phase 2 329-65-7 838
42
Glimepiride Approved Phase 4 93479-97-1 3476
43
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
44
Toremifene Approved, Investigational Phase 4 89778-26-7 3005573
45
Saxagliptin Approved Phase 4 361442-04-8 11243969
46
Methionine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 63-68-3 6137
47
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1406-16-2
48
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 65-23-6 1054
49
Choline Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 62-49-7 305
50
Tocopherol Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1406-66-2 14986

Interventional clinical trials:

(show top 50) (show all 924)
# Name Status NCT ID Phase Drugs
1 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
2 Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
3 The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver Unknown status NCT01956825 Phase 4
4 Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
5 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis Unknown status NCT02051842 Phase 4 Metadoxine
6 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
7 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
8 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
9 Complex Imaging Assessment of Steatosis Unknown status NCT02669641 Phase 4
10 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
11 Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
12 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
13 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4 Valsartan;Hydrochlorothiazide
14 Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy Unknown status NCT02652884 Phase 4 phosphate and betamethasone acetate, 2 mL.;saline 0.9% NaCl
15 Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
16 Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease Completed NCT01006889 Phase 4 Exenatide
17 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
18 The Effect of Vitamin D Supplementation in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
19 Liver Safety Under Upfront Arimidex vs Tamoxifen Completed NCT00537771 Phase 4 Anastrozole;Tamoxifen
20 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
21 Antidiabetic Effects on Intrahepatic Fat Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
22 Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
23 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
24 The Effects of PXR Activation on Hepatic Fat Content Completed NCT02329405 Phase 4 Rifampicin;Placebo
25 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
26 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
27 Pioglitazone in Hepatitis C Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
28 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes Completed NCT00998335 Phase 4 Long-acting bedtime insulin detemir (Levemir);Insulin detemir and pre-meal insulin aspart.
29 Weight Loss Improves Renal Hemodynamics Completed NCT01356394 Phase 4
30 Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl Completed NCT00533559 Phase 4 sodium phenylbutyrate;Placebo
31 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
32 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)
33 Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
34 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
35 Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
36 Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection Completed NCT01900015 Phase 4 Raltegravir;Efavirenz
37 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism Completed NCT02102646 Phase 4 Triptorelin
38 Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
39 Use of Metformin in Treatment of Childhood Obesity Completed NCT02274948 Phase 4 Metformin;Placebo
40 Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone Completed NCT02733679 Phase 4 Metformin;Pioglitazone
41 Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent Completed NCT02660047 Phase 4 Liraglutide;Liraglutide - Placebo
42 Lactate Metabolism Study in HIV Infected Persons Completed NCT00202228 Phase 4 cofactor supplementation (thiamine, riboflavin, L-carnitine)
43 A Study of the Effects of Exercise Intensity on Insulin Sensitivity in Overweight Youth Completed NCT00755547 Phase 4
44 Adding Liraglutide to High Dose Insulin: Breaking the Cycle Completed NCT01505673 Phase 4 Liraglutide;Saline
45 Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1. Completed NCT00107653 Phase 4 Ribavirin;Peginterferon alfa-2a;Ribavirin;Peginterferon alfa-2a
46 SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies Completed NCT01744236 Phase 4 Liraglutide;Sitagliptin;Exenatide;Liraglutide placebo;Sitagliptin placebo;Exenatide placebo;L-NMMA
47 Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) Completed NCT02277587 Phase 4 Plenadren;Conventional glucocorticoid therapy
48 Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes Recruiting NCT02303730 Phase 4 Exenatide;insulin glargine
49 SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD Recruiting NCT02649465 Phase 4 Tofogliflozin;Glimepiride
50 Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Recruiting NCT02500147 Phase 4 Metformin;Placebo

Search NIH Clinical Center for Fatty Liver Disease

Cochrane evidence based reviews: fatty liver

Sources

Genetic Tests for Fatty Liver Disease

About this section
Sources

Anatomical Context for Fatty Liver Disease

About this section

MalaCards organs/tissues related to Fatty Liver Disease:

41
Liver, Testes, Heart, Skin, Eye, Endothelial, Kidney
Sources

Publications for Fatty Liver Disease

About this section

Articles related to Fatty Liver Disease:

(show top 50) (show all 2179)
# Title Authors Year
1
Obestatin protects and reverses nonalcoholic fatty liver disease and its associated insulin resistance in rats via inhibition of food intake, enhancing hepatic adiponectin signaling, and blocking ghrelin acylation. ( 29429367 )
2018
2
Simultaneous quantification of hepatic MRI-PDFF and R2* in a rabbit model with nonalcoholic fatty liver disease. ( 29934919 )
2018
3
Chicory (Cichorium intybus L.) polysaccharides attenuate high-fat diet induced non-alcoholic fatty liver disease via AMPK activation. ( 29964102 )
2018
4
Taurine attenuates the development of hepatic steatosis through the inhibition of oxidative stress in a model of nonalcoholic fatty liver disease in vivo and in vitro. ( 29946793 )
2018
5
Nonalcoholic Fatty Liver Disease: Time to Take the Bull by the Horns. ( 29963461 )
2018
6
Role of genetic and metabolism in non-alcoholic fatty liver disease. ( 29442484 )
2018
7
Effects of isomaltulose on insulin resistance and metabolites in patients with nona89alcoholic fatty liver disease: A metabolomic analysis. ( 29956790 )
2018
8
Noninvasive Quantitative Detection Methods of Liver Fat Content in Nonalcoholic Fatty Liver Disease. ( 29951367 )
2018
9
PNPLA3: A Determinant of Response to Low-Fructose Diet in Nonalcoholic Fatty Liver Disease. ( 29452087 )
2018
10
A Case-control Study to Evaluate the Prevalence of Nonalcoholic Fatty Liver Disease Among Patients with Moderate-to-severe Psoriasis. ( 29942422 )
2018
11
Exploring the relationship between nonalcoholic fatty liver disease and pancreatic cancer by computed tomographic survey. ( 29235054 )
2018
12
Statin Use In Cirrhosis from Fatty Liver Disease. ( 29443384 )
2018
13
Urea cycle dysregulation in non-alcoholic fatty liver disease. ( 29981428 )
2018
14
Practical Dietary Recommendations for the Prevention and Management of Nonalcoholic Fatty Liver Disease in Adults. ( 29438460 )
2018
15
The Fatty Liver Index: A Simple and Accurate Predictor of Colorectal Adenoma in an Average-Risk Population. ( 29219920 )
2018
16
Hepatic loss of <i>Lissencephaly 1</i> (<i>Lis1</i>) induces fatty liver and accelerates liver tumorigenesis in mice. ( 29475944 )
2018
17
Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why liver biopsy is essential. ( 29427497 )
2018
18
Validation of simple indexes for nonalcoholic fatty liver disease in western China: a retrospective cross-sectional study. ( 29434074 )
2018
19
Personalized therapy when tackling nonalcoholic fatty liver disease: a focus on sex, genes, and drugs. ( 29969922 )
2018
20
Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: Either non-obese or obese Chinese population. ( 29428103 )
2018
21
The Influence of Gut Microbial Metabolism on the Development and Progression of Non-alcoholic Fatty Liver Disease. ( 29956209 )
2018
22
Normal serum alanine aminotransferase and non-alcoholic fatty liver disease among Korean adolescents: a cross-sectional study using data from KNHANES 2010-2015. ( 29976192 )
2018
23
Correction: Prospective comparison among transient elastography, supersonic shear imaging, and ARFI imaging for predicting fibrosis in nonalcoholic fatty liver disease. ( 29944727 )
2018
24
Changes in inflammatory factors and prognosis of patients complicated with non-alcoholic fatty liver disease undergoing coronary artery bypass grafting. ( 29434690 )
2018
25
Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease. ( 29956204 )
2018
26
Future therapy for non-alcoholic fatty liver disease. ( 29427492 )
2018
27
Evaluation of nonalcoholic fatty liver disease using magnetic resonance in obese children and adolescents. ( 29438686 )
2018
28
Non-alcoholic fatty liver disease severity is modulated by transglutaminase type 2. ( 29449533 )
2018
29
Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease. ( 29368124 )
2018
30
Daily Consumption of Synbiotic Yogurt Decreases Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial. ( 29931231 )
2018
31
Huperzine A attenuates nonalcoholic fatty liver disease by regulating hepatocyte senescence and apoptosis: an in vitro study. ( 29967757 )
2018
32
Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice. ( 29404514 )
2018
33
Decreased Hepatic Lactotransferrin Induces Hepatic Steatosis in Chronic Non-Alcoholic Fatty Liver Disease Model. ( 29975946 )
2018
34
Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030. ( 29956688 )
2018
35
Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase Activity in the Serum of Patients with Non-alcoholic Fatty Liver Disease. ( 29970524 )
2018
36
Associations of hyperuricemia and obesity with remission of nonalcoholic fatty liver disease among Chinese men: A retrospective cohort study. ( 29415050 )
2018
37
Chronic heart failure in patients with nonalcoholic fatty liver disease: prevalence, clinical features, and relevance. ( 29968484 )
2018
38
Relationship between diverticulosis and nonalcoholic fatty liver disease in elderly patients. ( 29432700 )
2018
39
Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease. ( 29441049 )
2018
40
A comprehensive bioinformatics analysis on multiple Gene Expression Omnibus datasets of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. ( 29769552 )
2018
41
<i>Helicobacter pylori</i> Infection Is Not Associated with Non-alcoholic Fatty Liver Disease: A Cross-Sectional Study in China. ( 29445363 )
2018
42
Association of Lipoprotein-Associated Phospholipase A2 with the Prevalence of Nonalcoholic Fatty Liver Disease: A Result from the APAC Study. ( 29973631 )
2018
43
Effects of liraglutide, metformin, and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: a randomized trial. ( 29957886 )
2018
44
Nonalcoholic Fatty Liver Disease in University Rugby Football Players. ( 29973915 )
2018
45
Bile acid metabolism and signaling: potential therapeutic target for nonalcoholic fatty liver disease. ( 29955036 )
2018
46
Increase in the skeletal muscle mass to body fat mass ratio predicts the decline in transaminase in patients with nonalcoholic fatty liver disease. ( 29948305 )
2018
47
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. ( 29971527 )
2018
48
Sarcopenia and risk of nonalcoholic fatty liver disease: A meta-analysis. ( 29451179 )
2018
49
Developmental Origins of Nonalcoholic Fatty Liver Disease (NAFLD). ( 29956192 )
2018
50
Association between nonalcoholic fatty liver disease and colorectal Tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis. ( 29935236 )
2018
Sources

Variations for Fatty Liver Disease

About this section
Sources

Expression for Fatty Liver Disease

About this section
Search GEO for disease gene expression data for Fatty Liver Disease.
Sources

Pathways for Fatty Liver Disease

About this section

Pathways related to Fatty Liver Disease according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. 66
Show member pathways
 13.4 ADIPOQ ADIPOR2 CYP2E1 INS INSR LEP
2
Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) 66
Show member pathways
 12.79 ADIPOQ FABP1 LEP PPARA SREBF1 TNF
3
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 65
Show member pathways
 12.77 ADIPOQ INS INSR LEP RETN TNF
4
Glucose / Energy Metabolism 4
12.38 ADIPOQ FABP1 INS INSR SREBF1
5
Angiopoietin Like Protein 8 Regulatory Pathway 1
Show member pathways
 12.36 INS INSR MAPK8 MLXIPL SREBF1
6
Prolactin Signaling Pathway 1 37
Show member pathways
 12.34 INS LEP LEPR MAPK8
7
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.28 ADIPOQ ADIPOR2 INS INSR LEP LEPR
8
Integration of energy metabolism 66
Show member pathways
 12.24 ADIPOQ ADIPOR2 INS MLXIPL
10
Apoptosis and survival Caspase cascade 22
Show member pathways
 12.07 KRT18 MAPK8 SREBF1 TNF
11
Longevity regulating pathway 37
Show member pathways
 12.03 ADIPOQ ADIPOR2 INS INSR
12
Type II diabetes mellitus 37 1
Show member pathways
 11.81 ADIPOQ INS INSR MAPK8 TNF
13
Insulin resistance 37
Show member pathways
 11.74 INS INSR MAPK8 MLXIPL PPARA SREBF1
14
PPAR signaling pathway 37
11.6 ADIPOQ FABP1 PPARA
15
AGE/RAGE pathway 1
11.55 INS INSR MAPK8
16
Signaling events mediated by PTP1B 1
11.46 INS INSR LEP LEPR
17
Adipogenesis 1
11.35 ADIPOQ INS LEP PNPLA3 PPARA RETN
18
Adipocytokine signaling pathway 37
11.34 ADIPOQ ADIPOR2 LEP LEPR MAPK8 PPARA
19
Transcription_Transcription factor Tubby signaling pathways 22
11.17 INS INSR MAPK8
20
Transcription factor regulation in adipogenesis 1
11 ADIPOQ INSR LEP MAPK8 TNF
21
Cori Cycle 1
10.8 GPT INS
Sources

GO Terms for Fatty Liver Disease

About this section

Biological processes related to Fatty Liver Disease according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.99 FABP1 INS INSR KRT18 LEP MAPK8
2 lipid metabolic process GO:0006629 9.97 ADIPOR2 LEP MTTP PNPLA3 PPARA SREBF1
3 cellular response to insulin stimulus GO:0032869 9.84 ADIPOQ INSR SREBF1
4 cholesterol metabolic process GO:0008203 9.84 LEP LEPR SREBF1
5 insulin receptor signaling pathway GO:0008286 9.83 INS INSR SREBF1
6 positive regulation of protein kinase B signaling GO:0051897 9.83 INS INSR LEP TNF
7 response to nutrient GO:0007584 9.82 ADIPOQ ADIPOR2 LEP
8 response to glucose GO:0009749 9.82 ADIPOQ INS SREBF1
9 regulation of insulin secretion GO:0050796 9.78 LEP SREBF1 TNF
10 circadian rhythm GO:0007623 9.73 ADIPOQ LEP MTTP SREBF1
11 negative regulation of lipid catabolic process GO:0050995 9.7 INS TNF
12 leukocyte tethering or rolling GO:0050901 9.7 LEP TNF
13 regulation of protein secretion GO:0050708 9.7 INS TNF
14 positive regulation of cellular protein metabolic process GO:0032270 9.69 ADIPOQ INS
15 positive regulation of insulin receptor signaling pathway GO:0046628 9.69 INS LEP
16 positive regulation of glycogen biosynthetic process GO:0045725 9.69 INS INSR
17 intestinal absorption GO:0050892 9.68 FABP1 LEP
18 positive regulation of lipid biosynthetic process GO:0046889 9.68 INS MLXIPL
19 energy reserve metabolic process GO:0006112 9.68 LEP LEPR
20 fatty acid oxidation GO:0019395 9.68 ADIPOQ ADIPOR2
21 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.67 ADIPOQ PPARA
22 fatty acid homeostasis GO:0055089 9.67 INS MLXIPL
23 response to insulin GO:0032868 9.67 INS LEP PPARA RETN
24 negative regulation of glucose import GO:0046325 9.66 LEP TNF
25 sexual reproduction GO:0019953 9.65 LEP LEPR
26 negative regulation of lipid storage GO:0010888 9.64 LEP TNF
27 negative regulation of appetite GO:0032099 9.63 LEP PPARA
28 leptin-mediated signaling pathway GO:0033210 9.63 LEP LEPR
29 regulation of fatty acid biosynthetic process GO:0042304 9.62 ADIPOQ ADIPOR2
30 positive regulation of fatty acid beta-oxidation GO:0032000 9.62 FABP1 PPARA
31 glucose metabolic process GO:0006006 9.62 ADIPOQ INS LEP TNF
32 regulation of bone remodeling GO:0046850 9.6 LEP LEPR
33 negative regulation of feeding behavior GO:2000252 9.59 INS RETN
34 regulation of fatty acid metabolic process GO:0019217 9.58 PPARA SREBF1
35 positive regulation of respiratory burst GO:0060267 9.58 INS INSR
36 positive regulation of glycolytic process GO:0045821 9.58 INS INSR MLXIPL
37 neuron projection maintenance GO:1990535 9.57 INS INSR
38 adiponectin-activated signaling pathway GO:0033211 9.56 ADIPOQ ADIPOR2
39 response to nutrient levels GO:0031667 9.56 ADIPOQ INS LEP PPARA
40 positive regulation of protein complex disassembly GO:0043243 9.55 INSR TNF
41 positive regulation of developmental growth GO:0048639 9.54 INSR LEP
42 positive regulation of fatty acid metabolic process GO:0045923 9.48 ADIPOQ PPARA
43 bone growth GO:0098868 9.46 LEP LEPR
44 negative regulation of gluconeogenesis GO:0045721 9.33 ADIPOQ INS LEPR
45 positive regulation of glucose import GO:0046326 9.26 ADIPOQ ADIPOR2 INS INSR
46 glucose homeostasis GO:0042593 9.17 ADIPOQ ADIPOR2 INS INSR LEP LEPR
47 regulation of signaling receptor activity GO:0010469 10.01 ADIPOQ INS LEP RETN TNF

Molecular functions related to Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin-like growth factor receptor binding GO:0005159 8.96 INS INSR
2 hormone activity GO:0005179 8.92 ADIPOQ INS LEP RETN
Sources

Sources for Fatty Liver Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....